Taysha gene therapies reports third quarter 2022 financial results and provides corporate update

$50 million strategic investment from astellas pharma to support development of tsha-120 in giant axonal neuropathy (gan) and tsha-102 in rett syndrome
TSHA Ratings Summary
TSHA Quant Ranking